DUBLIN--(BUSINESS WIRE)--Jul 9, 2018--The "Pulmonary Arterial Hypertension (PAH) Therapeutics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets.

This report analyzes the worldwide markets in US$ Million.

The global market is analyzed by the following Drug Class and Brands:

Endothelin Receptor Antagonist (Letairis/Volibris, Macitentan, Thelin, & Tracleer) Prostacyclin and Prostacyclin Analogs (Epoprostenol/Veletri*, Flolan, Remodulin, Selexipag, Tyvaso, Ventavis, & Orenitram) PDE-5 Inhibitors (Cialis/Adcirca, & Revatio) Soluble Guanylate Cyclase (sGC) Stimulator (Riociguat)

The report profiles 31 companies including many key and niche players such as:

Actelion Pharmaceuticals Ltd (Switzerland) Bayer AG (Germany) Gilead Sciences, Inc. (US) Pfizer, Inc. (US) United Therapeutics Corporation (US) Lung Biotechnology PBC (US)

Key Topics Covered

1. INDUSTRY OVERVIEW

Pulmonary Arterial Hypertension (PAH) - A Prelude Current & Future Analysis PAH Drugs Market by Class The PAH Classification PH Patient Groupings as per World Health Organization Classification of PAH patients as per New York Heart Association (NYHA) Oral Therapies lead the Global PAH Therapeutics Market Combination Therapy Favored over Monotherapy for PAH Pediatric PAH - A Potential Market with Unmet Need Inflammation: New Target for PAH Therapeutics Aging Population & PAH

2. COMPETITIVE SCENARIO

3. PAH PIPELINE

4. PRODUCT OVERVIEW

5. PRODUCT INNOVATIONS & APPROVALS

6. RECENT INDUSTRY ACTIVITY

7. FOCUS ON SELECT GLOBAL PLAYERS

8. GLOBAL MARKET PERSPECTIVE

Total Companies Profiled: 31 (including Divisions/Subsidiaries 33)

The United States (18) Japan (3) Europe (10) France (1)Germany (3)The United Kingdom (3)Rest of Europe (3) Asia-Pacific (Excluding Japan) (1) Middle East (1)

For more information about this report visit https://www.researchandmarkets.com/research/l7bj7r/global_strategic?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180709005572/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Cardiovascular Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH CARDIOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 07/09/2018 10:37 AM/DISC: 07/09/2018 10:37 AM

http://www.businesswire.com/news/home/20180709005572/en